Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study

Carla Colombo, Andrea Crosignani, Marisa Assaisso, Pier Maria Battezzati, Mauro Podda, Annamaria Giunta, Linda Zimmer-Nechemias, Kenneth D R Setchell

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10 to 15 mg/kg body wt/day) of ursodeoxycholic acid are given to other liver disease patients; this may be explained by the bile acid malabsorption that is characteristic of the disease. For this reason a dose-response study was carried out in nine cystic fibrosis patients with liver disease to establish whether improved efficacy could be obtained with higher doses. Ursodeoxycholic acid in doses of 5,10 and 15 mg/kg body wt/day was given orally for consecutive 2-mo periods in a replicated Latinsquare design. After this, all patients received 20 mg/kg body wt/day. Liver function, individual serum bile acids and biliary bile acid composition were determined at entry and at the end of each treatment period. Our data demonstrate that the magnitude of the biochemical improvement in serum liver enzymes was significantly greater with higher doses of ursodeoxy-cholic acid; at 20 mg/kg body wt/day it was similar to that reported for patients with other liver diseases administered lower doses. Biliary ursodeoxycholic acid enrichment increased with increasing doses, attaining 42% ± 6% of the total biliary bile acids with the highest dose. Fasting serum ursodeoxycholic acid concentrations increased during ursodeoxycholic acid administration but were variable and correlated poorly with the dose of ursodeoxycholic acid administered, whereas no correlation was found between serum ursodeoxycholic acid concentration and the proportion of ursodeoxycholic acid in bile. Our data indicate a need for doses of ursodeoxycholic acid of 20 mg/kg body wt/day or greater to obtain optimal improvement in biochemical indices of liver function and biliary ursodeoxycholic acid enrichment in cystic fibrosis patients with associated liver disease.

Original languageEnglish
Pages (from-to)924-930
Number of pages7
JournalHepatology
Volume16
Issue number4
Publication statusPublished - Oct 1992

Fingerprint

Ursodeoxycholic Acid
Cystic Fibrosis
Liver Diseases
Bile Acids and Salts
Therapeutics
Liver
Serum
Cholic Acid
Bile
Fasting
Biomarkers

ASJC Scopus subject areas

  • Hepatology

Cite this

Colombo, C., Crosignani, A., Assaisso, M., Battezzati, P. M., Podda, M., Giunta, A., ... Setchell, K. D. R. (1992). Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology, 16(4), 924-930.

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease : A dose-response study. / Colombo, Carla; Crosignani, Andrea; Assaisso, Marisa; Battezzati, Pier Maria; Podda, Mauro; Giunta, Annamaria; Zimmer-Nechemias, Linda; Setchell, Kenneth D R.

In: Hepatology, Vol. 16, No. 4, 10.1992, p. 924-930.

Research output: Contribution to journalArticle

Colombo, C, Crosignani, A, Assaisso, M, Battezzati, PM, Podda, M, Giunta, A, Zimmer-Nechemias, L & Setchell, KDR 1992, 'Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study', Hepatology, vol. 16, no. 4, pp. 924-930.
Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology. 1992 Oct;16(4):924-930.
Colombo, Carla ; Crosignani, Andrea ; Assaisso, Marisa ; Battezzati, Pier Maria ; Podda, Mauro ; Giunta, Annamaria ; Zimmer-Nechemias, Linda ; Setchell, Kenneth D R. / Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease : A dose-response study. In: Hepatology. 1992 ; Vol. 16, No. 4. pp. 924-930.
@article{b16ef9cef44e4ac3b63c34c5169c900e,
title = "Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study",
abstract = "Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10 to 15 mg/kg body wt/day) of ursodeoxycholic acid are given to other liver disease patients; this may be explained by the bile acid malabsorption that is characteristic of the disease. For this reason a dose-response study was carried out in nine cystic fibrosis patients with liver disease to establish whether improved efficacy could be obtained with higher doses. Ursodeoxycholic acid in doses of 5,10 and 15 mg/kg body wt/day was given orally for consecutive 2-mo periods in a replicated Latinsquare design. After this, all patients received 20 mg/kg body wt/day. Liver function, individual serum bile acids and biliary bile acid composition were determined at entry and at the end of each treatment period. Our data demonstrate that the magnitude of the biochemical improvement in serum liver enzymes was significantly greater with higher doses of ursodeoxy-cholic acid; at 20 mg/kg body wt/day it was similar to that reported for patients with other liver diseases administered lower doses. Biliary ursodeoxycholic acid enrichment increased with increasing doses, attaining 42{\%} ± 6{\%} of the total biliary bile acids with the highest dose. Fasting serum ursodeoxycholic acid concentrations increased during ursodeoxycholic acid administration but were variable and correlated poorly with the dose of ursodeoxycholic acid administered, whereas no correlation was found between serum ursodeoxycholic acid concentration and the proportion of ursodeoxycholic acid in bile. Our data indicate a need for doses of ursodeoxycholic acid of 20 mg/kg body wt/day or greater to obtain optimal improvement in biochemical indices of liver function and biliary ursodeoxycholic acid enrichment in cystic fibrosis patients with associated liver disease.",
author = "Carla Colombo and Andrea Crosignani and Marisa Assaisso and Battezzati, {Pier Maria} and Mauro Podda and Annamaria Giunta and Linda Zimmer-Nechemias and Setchell, {Kenneth D R}",
year = "1992",
month = "10",
language = "English",
volume = "16",
pages = "924--930",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease

T2 - A dose-response study

AU - Colombo, Carla

AU - Crosignani, Andrea

AU - Assaisso, Marisa

AU - Battezzati, Pier Maria

AU - Podda, Mauro

AU - Giunta, Annamaria

AU - Zimmer-Nechemias, Linda

AU - Setchell, Kenneth D R

PY - 1992/10

Y1 - 1992/10

N2 - Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10 to 15 mg/kg body wt/day) of ursodeoxycholic acid are given to other liver disease patients; this may be explained by the bile acid malabsorption that is characteristic of the disease. For this reason a dose-response study was carried out in nine cystic fibrosis patients with liver disease to establish whether improved efficacy could be obtained with higher doses. Ursodeoxycholic acid in doses of 5,10 and 15 mg/kg body wt/day was given orally for consecutive 2-mo periods in a replicated Latinsquare design. After this, all patients received 20 mg/kg body wt/day. Liver function, individual serum bile acids and biliary bile acid composition were determined at entry and at the end of each treatment period. Our data demonstrate that the magnitude of the biochemical improvement in serum liver enzymes was significantly greater with higher doses of ursodeoxy-cholic acid; at 20 mg/kg body wt/day it was similar to that reported for patients with other liver diseases administered lower doses. Biliary ursodeoxycholic acid enrichment increased with increasing doses, attaining 42% ± 6% of the total biliary bile acids with the highest dose. Fasting serum ursodeoxycholic acid concentrations increased during ursodeoxycholic acid administration but were variable and correlated poorly with the dose of ursodeoxycholic acid administered, whereas no correlation was found between serum ursodeoxycholic acid concentration and the proportion of ursodeoxycholic acid in bile. Our data indicate a need for doses of ursodeoxycholic acid of 20 mg/kg body wt/day or greater to obtain optimal improvement in biochemical indices of liver function and biliary ursodeoxycholic acid enrichment in cystic fibrosis patients with associated liver disease.

AB - Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10 to 15 mg/kg body wt/day) of ursodeoxycholic acid are given to other liver disease patients; this may be explained by the bile acid malabsorption that is characteristic of the disease. For this reason a dose-response study was carried out in nine cystic fibrosis patients with liver disease to establish whether improved efficacy could be obtained with higher doses. Ursodeoxycholic acid in doses of 5,10 and 15 mg/kg body wt/day was given orally for consecutive 2-mo periods in a replicated Latinsquare design. After this, all patients received 20 mg/kg body wt/day. Liver function, individual serum bile acids and biliary bile acid composition were determined at entry and at the end of each treatment period. Our data demonstrate that the magnitude of the biochemical improvement in serum liver enzymes was significantly greater with higher doses of ursodeoxy-cholic acid; at 20 mg/kg body wt/day it was similar to that reported for patients with other liver diseases administered lower doses. Biliary ursodeoxycholic acid enrichment increased with increasing doses, attaining 42% ± 6% of the total biliary bile acids with the highest dose. Fasting serum ursodeoxycholic acid concentrations increased during ursodeoxycholic acid administration but were variable and correlated poorly with the dose of ursodeoxycholic acid administered, whereas no correlation was found between serum ursodeoxycholic acid concentration and the proportion of ursodeoxycholic acid in bile. Our data indicate a need for doses of ursodeoxycholic acid of 20 mg/kg body wt/day or greater to obtain optimal improvement in biochemical indices of liver function and biliary ursodeoxycholic acid enrichment in cystic fibrosis patients with associated liver disease.

UR - http://www.scopus.com/inward/record.url?scp=0026665209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026665209&partnerID=8YFLogxK

M3 - Article

C2 - 1398498

AN - SCOPUS:0026665209

VL - 16

SP - 924

EP - 930

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -